Short fractions of oligofructose are preferentially metabolized by Bifidobacterium animalis DN-173 010

The growth of Bifidobacterium animalis DN-173 010 on different energy sources was studied through small- and large-scale fermentations. Growth on both more common energy sources (glucose, fructose, galactose, lactose, and sucrose) and inulin-type fructans was examined. High-performance liquid chromatography analysis was used to investigate the kinetics. Gas chromatography was used to determine the fructan degradation during the fermentation process. B. animalis DN-173 010 was unable to grow on a medium containing glucose as the sole energy source. In general, monosaccharides were poor growth substrates for the B. animalis strain. The fermentations with the inulin-type fructans resulted in changes in both growth and metabolite production due to the preferential metabolism of certain fructans, especially the short-chain oligomers. Only after depletion of the shorter chains were the larger fractions also metabolized, although to a lesser extent. Acetic acid was the major metabolite produced during all fermentation experiments. At the beginning of the fermentation, high levels of lactic acid were produced, which were partially replaced by formic acid at later stages. This suggests a shift in sugar metabolism to gain additional ATP that is necessary for growth on oligofructose, which is metabolized more slowly.     

Survival of Bifidobacterium animalis DN-173 010 in the faecal microbiota after administration in lyophilised form or in fermented product - a randomised study in healthy adults

The survival of Bifidobacterium animalis strain DN-173 010 was assessed after its ingestion in a fermented product or in a lyophilised form. Twelve healthy subjects were included in a randomised, open study with 2 parallel groups. The composition and activities of the faecal microbiota were monitored before (10-day baseline step), during (1-week product administration step) and after (10-day follow-up step) the ingestion of 1 of the 2 products. A colony immunoblotting method, fluorescent in situ hybridisation with group-specific DNA probes, and temporal temperature gradient gel electrophoresis using group-specific primers were carried out to compare survival of B. animalis strain DN-173 010 after ingestion of the 2 products, together with analyses of enzyme activities and faecal metabolites. At the end of the supplementation step, the mean number of B. animalis DN-173 010 quantified by immunodetection in the faeces of 5 of 6 subjects in each treatment group was >/=10(8) colony-forming units/g faeces. These numbers corresponded to an average survival of 22% for the lyophilised form and 20% for the fermented product. At the same step, the PCR temporal temperature gradient gel electrophoresis profiles showed a double band corresponding to the B. animalis DN-173 010 pattern for 11 subjects. No major modification was observed during the trial in either the dominant members of the faecal microbiota assessed by fluorescent in situ hybridisation or their activities. In conclusion, we show that the lyophilised form of B. animalis DN-173 010 survives transit and could represent a more convenient form to administer for long-term clinical trials.     

Bile Affects the Synthesis of Exopolysaccharides by Bifidobacterium animalis

By using cryo-scanning electron microscopy and quantification with lectin-conjugated probes, we have detected the production of exopolysaccharides (EPS) in Bifidobacterium animalis subsp. lactis in the presence of bile. In addition, the expression of gtf01207, which codifies a putative priming glycosyltransferase involved in EPS synthesis, was induced by bile.     

Transport of glucose by Bifidobacterium animalis subsp. lactis occurs via facilitated diffusion

Two strains of Bifidobacterium animalis subsp. lactis were indistinguishable by several nucleic acid-based techniques; however, the type strain DSMZ 10140 was glucose utilization positive, while RB 4825, an industrially employed strain, was unable to grow rapidly on glucose as the principal carbon source. This difference was attributed to the presence of a low-affinity facilitated-diffusion glucose transporter identified in DSMZ 10140 but lacking in RB 4825. Uptake of D-[U-(14)C]glucose in DSMZ 10140 was stimulated by monovalent cations (ammonium, sodium, potassium, and lithium) and inhibited by divalent cations (calcium and magnesium). When competitor carbohydrates were included in the uptake assays, stereospecific inhibition was exhibited, with greater competition by methyl-beta-glucoside than methyl-alpha-glucoside. Significant inhibition (>30%) was observed with phloretin, an inhibitor of facilitated diffusion of glucose, whereas there was no inhibition by sodium fluoride, iodoacetate, sodium arsenate, sodium azide, 2,4-dinitrophenol, monensin, or valinomycin, which typically reduce energy-driven transport. Based on kinetic analyses, the mean values for K(t) and V(max) were 14.8 +/- 3.4 mM D-glucose and 0.13 +/- 0.03 micromol glucose/min/mg cell protein, respectively. Glucose uptake by several glucose-utilizing commercial strains of B. animalis subsp. lactis was also inhibited by phloretin, indicating the presence of facilitated diffusion glucose transporters in those strains. Since DSMZ 10140 has been previously reported to lack a functional glucose phosphoenolpyruvate phosphotransferase system, the glucose transporter identified here is responsible for much of the organism's glucose uptake.     

Complete genome sequence of Bifidobacterium animalis subsp. lactis BLC1

Bifidobacterium animalis subsp. lactis BLC1 is a probiotic bacterium that is widely exploited by food industries as the active ingredient of various functional foods. Here we report the complete genome sequence of B. animalis subsp. lactis BLC1, which is expected to provide insights into the biology of this health-promoting microorganism and improve our understanding of its phylogenetic relatedness with other members of the B. animalis subsp. lactis taxon.     

In Vitro Kinetic Analysis of Oligofructose Consumption by Bacteroides and Bifidobacterium spp. Indicates Different Degradation Mechanisms

The growth of pure cultures of Bacteroides thetaiotaomicron LMG 11262 and Bacteroides fragilis LMG 10263 on fructose and oligofructose was examined and compared to that of Bifidobacterium longum BB536 through in vitro laboratory fermentations. Gas chromatography (GC) analysis was used to determine the different fractions of oligofructose and their degradation during the fermentation process. Both B. thetaiotaomicron LMG 11262 and B. fragilis LMG 10263 were able to grow on oligofructose as fast as on fructose, succinic acid being the major metabolite produced by both strains. B. longum BB536 grew slower on oligofructose than on fructose. Acetic acid and lactic acid were the main metabolites produced when fructose was used as the sole energy source. Increased amounts of formic acid and ethanol were produced when oligofructose was used as an energy source at the cost of lactic acid. Detailed kinetic analysis revealed a preferential metabolism of the short oligofructose fractions (e.g., F₂ and F₃) for B. longum BB536. After depletion of the short fractions, the larger oligofructose fractions (e.g., F₄, GF₄, F₅, GF₅, and F₆) were metabolized, too. Both Bacteroides strains did not display such a preferential metabolism and degraded all oligofructose fractions simultaneously, transiently increasing the fructose concentration in the medium. This suggests a different mechanism for oligofructose breakdown between the strain of Bifidobacterium and both strains of Bacteroides, which helps to explain the bifidogenic nature of inulin-type fructans.     

Identification of plasmalogens in the cytoplasmic membrane of Bifidobacterium animalis subsp. lactis

Plasmalogens are ether-linked lipids that may influence oxidative stress resistance of eukaryotic cell membranes. Since bacterial membrane composition can influence environmental stress resistance, we explored the prevalence of plasmalogens in the cytoplasmic membrane of Bifidobacterium animalis subsp. lactis. Results showed plasmalogens are a major component of the B. animalis subsp. lactis membrane.     

Complete Genome Sequence of Probiotic Bifidobacterium animalis subsp. lactis Strain V9

Bifidobacterium animalis subsp. lactis strain V9 is a Chinese commercial bifidobacteria with several probiotic functions. It was isolated from a healthy Mongolian child in China. We present here the complete genome sequence of V9 and compare it to 3 other published genome sequences of B. animalis subsp. lactis strains. The result indicates the lack of polymorphism among strains of this subspecies from different continents.Bifidobacterium animalis subsp. lactis strain V9 was isolated from the feces of a healthy Mongolian child in China (5). It has shown a high level of tolerance to gastric acid and bile acids (5). This strain has been implemented in the industrial production of dairy starter cultures by Inner Mongolia Yili Industrial Group Company Limited, the largest dairy corporation in China.Whole-genome sequencing of B. animalis subsp. lactis V9 was performed with a combined strategy of 454 sequencing (8) and Solexa paired-end sequencing technology (2). Genomic libraries containing 7-kb inserts were constructed, and 325,824 paired-end reads and 67,177 single-end reads were generated using the GS FLX system, giving 36.0-fold coverage of the genome. A total of 96.0% of the reads were assembled into four large scaffolds, including 163 nonredundant contigs, using the 454 Newbler assembler (454 Life Sciences, Branford, CT). A total of 8,953,102 reads (2-kb library) were generated to reach a depth of 335-fold coverage with an Illumina Solexa Genome Analyzer IIx and mapped to the scaffolds using the Burrows-Wheeler Alignment (BWA) tool (7). The gaps between scaffolds were filled by sequencing PCR products using an ABI 3730 capillary sequencer. The analysis of the genome was performed as described previously (3, 4).The complete genome sequence of V9 contains a circular 1,944,050-bp chromosome, with a GC content of 60.5%. The genome size is slightly larger than the sequenced genome sizes of B. animalis subsp. lactis strains DSM 10140^T (1), Bl-04 (1), and AD011 (6) due to a unique insertion of 4,037 bp. The V9 genome contains 1,636 genes in total, including 1,572 coding genes, 4 rRNA operons, and 52 tRNAs.Comparison of the four B. animalis subsp. lactis genomes revealed nearly perfect synteny. AD011 is the most diverged strain, with more single nucleotide polymorphisms (SNPs) and indels than the other three strains. There are 197 SNPs in AD011, with 70 synonymous and 16 nonsynonymous SNPs, which means that there is only 1 SNP per 10 kb, indicating the high consistency within this subspecies. The other three strains are almost identical, with only 25 SNPs in V9, 13 SNPs in Bl-04, and 44 SNPs in DSM 10140^T. Strain V9 was isolated from the feces of a Mongolian child in Inner Mongolia, China, where traditional fermented milk has been consumed for thousands of years, and the other three strains were originally isolated from fecal samples (1, 6) or yogurt (1) in the United States of America, France, and Korea. The result indicated the lack of polymorphism among multiple lineages from different continents (1).Interestingly, compared to the other three sequenced B. animalis subsp. lactis strains, V9 has a large insertion, which encodes one putative transposase (BalV_1091) and two sugar metabolism-related proteins, an alpha-1,4-glucosidase (BalV_1092) and an ABC transporter solute-binding protein (BalV_1093). This insertion is a copy of the region at positions 1,860,164 to 1,864,073, which is commonly shared by all four B. animalis subsp. lactis strains.     

Genome Sequence of the Probiotic Bacterium Bifidobacterium animalis subsp. lactis AD011

Bifidobacterium animalis subsp. lactis is a probiotic bacterium that naturally inhabits the guts of most mammals, including humans. Here we report the complete genome sequence of B. animalis subsp. lactis AD011 that was isolated from an infant fecal sample. Biological functions encoded in a single circular chromosome of 1,933,695 bp, smallest among the completely sequenced bifidobacterial genomes, are suggestive of their probiotic functions, such as utilization of bifidogenic factors and a variety of glycosidic enzymes and biosynthesis of polysaccharides.     

动物双歧杆菌肌球交叉反应抗原MCRA酶学功能的研究

目的:将肌球蛋白交叉反应抗原基因(Myosin cross reactive antigen,MCRA)在毕赤酵母中重组表达,对其酶学功能进行研究。方法:利用动物双歧杆菌BB-12(Bifidobacterium animalissubsp.lactis BB-12)的肌球交叉反应抗原(MCRA)基因序列特征设计引物进行PCR扩增后克隆至毕赤酵母表达载体pPinkα-HC,电转化获得PichiaPinkTM重组菌。通过SDS-PAGE和Westernblot检测重组蛋白的表达情况,GC-MS分析重组菌的脂质组成情况,最终确定重组蛋白的活性及其催化特性。结果:SDS-PAGE及Western blot结果表明动物双歧杆菌BB-12的MCRA蛋白在重组毕赤酵母菌PichiaPinkTMpPinkα-HC-MCRA中成功表达且定位至细胞膜,大小为82 kDa。GC-MS结果显示,添加底物亚油酸培养基后,重组菌将亚油酸转变为羟基化衍生物,产物为10-羟基-顺-12-十八碳烯酸(10-HOE)。结论:这是首次对该类蛋白成功定位后对其酶学功能进行研究,动物双歧杆菌BB-12的MCRA基因首次在毕赤酵母中实现了活性表达,产物为10-羟基-顺-12-十八碳烯酸。     

Stability of recombinant plasmids on the continuous culture of Bifidobacterium animalis ATCC 27536

Bifidobacterium animalis ATCC 27536 represents among bifidobacteria a host-model for cloning experiments. The segregational and structural stabilities of a family of cloning vectors with different molecular weights but sharing a common core were studied in continuous fermentation of the hosting B. animalis without selective pressure. The rate of plasmid loss (R) and the specific growth rate difference (delta mu) between plasmid-free and plasmid-carrying cells were calculated for each plasmid and their relationship with plasmid size was studied. It was observed that both R and the numerical value of delta mu increased exponentially with plasmid size. The exponential functions correlating the specific growth rate difference and the rate of plasmid loss with the plasmid molecular weight were determined. Furthermore, the smallest of the plasmids studied, pLAV (4.3-kb) was thoroughly characterized by means of its complete nucleotide sequence. It was found that it contained an extra DNA fragment, the first bifidobacterial insertion sequence characterised, named IS 1999.     

Strain-Specific Genotyping of Bifidobacterium animalis subsp. lactis by Using Single-Nucleotide Polymorphisms,Insertions, and Deletions

Several probiotic strains of Bifidobacterium animalis subsp. lactis are widely supplemented into food products and dietary supplements due to their documented health benefits and ability to survive within the mammalian gastrointestinal tract and acidified dairy products. The strain specificity of these characteristics demands techniques with high discriminatory power to differentiate among strains. However, to date, molecular approaches, such as pulsed-field gel electrophoresis and randomly amplified polymorphic DNA-PCR, have been ineffective at achieving strain separation due to the monomorphic nature of this subspecies. Previously, sequencing and comparison of two B. animalis subsp. lactis genomes (DSMZ 10140 and Bl-04) confirmed this high level of sequence similarity, identifying only 47 single-nucleotide polymorphisms (SNPs) and four insertions and/or deletions (INDELs) between them. In this study, we hypothesized that a sequence-based typing method targeting these loci would permit greater discrimination between strains than previously attempted methods. Sequencing 50 of these loci in 24 strains of B. animalis subsp. lactis revealed that a combination of nine SNPs/INDELs could be used to differentiate strains into 14 distinct genotypic groups. In addition, the presence of a nonsynonymous SNP within the gene encoding a putative glucose uptake protein was found to correlate with the ability of certain strains to transport glucose and to grow rapidly in a medium containing glucose as the sole carbon source. The method reported here can be used in clinical, regulatory, and commercial applications requiring identification of B. animalis subsp. lactis at the strain level.Probiotics are currently defined as live microorganisms which, when administered in adequate amounts, confer a health benefit on the host (12). Many of the organisms studied for their probiotic potential are members of lactic acid bacteria and the genus Bifidobacterium, which has resulted in their inclusion in a large variety of dietary supplements and food products. Relative to most bifidobacterial species of human origin, Bifidobacterium animalis subsp. lactis is less sensitive to stressful conditions (bile, acid, and oxygen) which might be encountered in the mammalian gastrointestinal tract or in fermented or acidified dairy products (7, 26, 28, 31, 37). B. animalis subsp. lactis is widely added to commercial products because it is better able to withstand the adverse conditions of starter culture and product manufacture and to maintain viability and stability during product shelf-life (30). Therefore, strains of B. animalis, specifically B. animalis subsp. lactis, have been found in the majority of probiotic-supplemented dairy products surveyed in North America (the United States and Canada) and Europe (Great Britain, France, Italy, and Germany) (6, 13-15, 21, 22, 28, 29, 32, 49).When selecting a probiotic microorganism to add to supplements or foods, the strain must be identified at the genus, species, and strain levels (40). Proper characterization of a strain is important for safety and quality assurance, for identifying and differentiating putative probiotic strains, and for understanding the interactions among members of gut microbiota. In addition, proper characterization is important to maintain consumer confidence. Product labels often list invalid names of organisms or misidentify the species the product contains, leading to consumer confusion (6, 16, 20, 28, 29, 35, 38, 49). In the case of Bifidobacterium, most dairy products sold in the United States do not identify species, and many only refer to the invalid name “Bifid” or “Bifidus.” At the very least, added microorganisms should be accurately identified to the species level on product labels.According to the FAO/WHO guidelines for probiotic use, specific health benefits observed in research using a specific strain cannot be extrapolated to other, closely related strains (12). Although most clinical studies of probiotic strains compare strains of different genera or different species, few studies have assessed the actual variability of expected health benefits within species or subspecies. However, it is reasonable to consider that health effects, like the phenotypic traits exhibited by strains within a species, are strain specific. Therefore, reliable techniques for the identification of probiotic organisms at the strain level are required.Characterization to the strain level has several important potential applications. Understanding the complex interactions among microorganisms in the intestinal ecosystem requires methods of differentiating a strain of interest from other strains of the same species contained in the autochthonous microbiota. Strain differentiation techniques also aid in assessing survival of a probiotic organism through the gastrointestinal system, which is particularly important for clinical trials and regulatory purposes (17). The ability to uniquely identify a strain also lends credibility to statements made about the potential health benefits of consuming a particular product containing a strain with demonstrated probiotic effects and supports the licensing or intellectual property rights of the manufacturer.The high degree of genome conservation observed between strains of B. animalis subsp. lactis in terms of size, organization, and sequence is indicative of a genomically monomorphic subspecies (2, 25; also HN019 GenBank project 28807). As an example, comparison of the complete genome sequences of two B. animalis subsp. lactis strains, DSMZ 10140 (the type strain) and Bl-04 (a commercial strain, also known as RB 4825) (2), identified 47 single-nucleotide polymorphisms (SNPs) in nonrepetitive elements, as well as 443 bp distributed among four INDEL sites: a 121-bp tRNA-encoding sequence, a 54-bp region within the long-chain fatty acid-coenzyme A ligase gene, a 214-bp region within the CRISPR (clustered regularly interspaced short palindromic repeats) locus, and a 54-bp intergenic sequence. Overall, this 99.975% genome identity explains the inability to differentiate these strains by techniques such as the sequencing of housekeeping genes, multilocus sequence typing, and pulsed-field gel electrophoresis (PFGE) (3, 9, 23, 39, 44-46, 50).The strain specificity of reported health benefits of probiotics and the frequent use of B. animalis subsp. lactis as a probiotic in food products and supplements demands techniques with greater discriminatory power to identify and differentiate among strains within this highly homogeneous group. Unfortunately, strain level differentiation of B. animalis subsp. lactis presents several challenges. Although Ventura and Zink were able to differentiate strains of B. animalis subsp. lactis by sequencing the 16S-23S internal transcribed sequence (ITS) region (47), analysis of the four ITS operons between DSMZ 10140 and Bl-04 indicated complete identity (2). However, SNPs and INDELs do have potential for strain differentiation. According to Achtman, focusing on polymorphic SNPs is a desirable approach for the typing of monomorphic species (1). Therefore, the objective of the present study was to exploit the previously identified SNP and INDEL sites to develop a technique capable of differentiating among a collection of B. animalis subsp. lactis strains obtained from culture collections and commercial starter culture companies.     

Antioxidant activity in vitro of the selenium-contained protein from the Se-enriched Bifidobacterium animalis 01

Several studies indicated that bifidobacteria possessed strong antioxidant activity. In present study, the antioxidant activities of Bifidobacterium animalis 01 proteins were evaluated using six assays, namely, linoleic acid preoxidation assay, erythrocyte hemolysis assay, 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay, reducing power assay, hydroxyl (OH) and superoxide radicals (O₂^?) assays, in which the last two assays were measured by electron spin resonance (ESR). There were two kinds of B. animalis 01 proteins in this study, the regular B. animalis 01 protein (Pro-CK) and the B. animalis 01 selenium-contained protein (Pro-Se). Both Pro-CK and Pro-Se showed concentration dependent antioxidant activity in DPPH assay, reducing power assay and erythrocyte hemolysis assay. All results of six assays indicated that the antioxidant activity of the B. animalis 01 protein was improved remarkably after selenium was incorporated. The antioxidant activity of Pro-Se increased with the increase of selenium content in Pro-Se suggesting selenium played a positive role in enhancing the antioxidant activity of B. animalis 01 protein. Moreover, organic selenium was more effective than inorganic selenium on enhancing the hydroxyl radical scavenging ability of B. animalis 01 protein.     

Genome sequence of the probiotic strain Bifidobacterium animalis subsp. lactis CNCM I-2494

Bifidobacterium animalis subsp. lactis CNCM I-2494 is part of a commercialized fermented dairy product with documented health benefits revealed by multiple randomized placebo-controlled clinical trials. Here we report the complete genome sequence of this strain, which has a circular genome of 1,943,113 bp with 1,660 open reading frames and 4 ribosomal operons.     

Comparative Genomics of Bifidobacterium animalis subsp. lactis Reveals a Strict Monophyletic Bifidobacterial Taxon

Strains of Bifidobacterium animalis subsp. lactis are extensively exploited by the food industry as health-promoting bacteria, although the genetic variability of members belonging to this taxon has so far not received much scientific attention. In this article, we describe the complete genetic makeup of the B. animalis subsp. lactis Bl12 genome and discuss the genetic relatedness of this strain with other sequenced strains belonging to this taxon. Moreover, a detailed comparative genomic analysis of B. animalis subsp. lactis genomes was performed, which revealed a closely related and isogenic nature of all currently available B. animalis subsp. lactis strains, thus strongly suggesting a closed pan-genome structure of this bacterial group.     

The F1F0-ATPase of Bifidobacterium animalis is involved in bile tolerance

Adaptation and tolerance to bile stress are important factors for the survival of bifidobacteria in the intestinal tract. Bifidobacterium animalis is a probiotic microorganism which has been largely applied in fermented dairy foods due to its technological properties and its health-promoting effects for humans. The effect of the presence of bile on the activity and expression of F₁F₀-ATPase, the pool of ATP and the intracellular pH of B. animalis IPLA 4549 and its mutant with acquired resistance to bile B. animalis 4549dOx was determined. The bile-resistant mutant tolerated the acid pH better than its parent strain. Bile induced the expression of the F₁F₀-ATPase and increased the membrane-bound H⁺-ATPase activity, in both parent and mutant strains. In acidic conditions (pH 5.0), the expression and the activity of this enzyme were higher in the mutant than in the parent strain when cells were grown in the absence of bile. Total ATP content was higher for the mutant in the absence of bile, whereas the presence of bile induced a decrease of intracellular ATP levels, which was much more pronounced for the parent strain. At pH 4.0, and independently on the presence or absence of bile, the mutant showed a higher intracellular pH than its parent strain. These findings suggest that the bile-adapted B. animalis strain is able to tolerate bile by increasing the intracellular ATP reserve, and by inducing proton pumping by the F₁F₀-ATPase, therefore tightly regulating the internal pH, and provide a link between the physiological state of the cell and the response to bile.     

Molecular characterization of bile salt hydrolase from Bifidobacterium animalis subsp. lactis Bi30

The present work describes the identification, purification, and characterization of bile salt hydrolase (BSH) from Bifidobacterium animalis subsp. lactis. The enzyme was purified to electrophoretic homogeneity by hydrophobic chromatography, ion-exchange chromatography and ultrafiltration. SDS-PAGE analysis of putative BSH and gel filtration revealed that the analyzed protein is presumably a tetramer composed of four monomers each of about 35 kDa. The purified enzyme was analyzed by liquid chromatography coupled to LTQ FT ICR mass spectrometry and unambiguously identified as a bile salt hydrolase from B. animalis. The isoelectric point of the studied protein was estimated to be around pH 4.9. The pH optimum of the purified BSH is between 4.7 to 6.5, and the temperature optimum is around 50 degrees C. The BSH of B. animalis could deconjugate all tested bile salts, with clear preference for glycine-conjugated bile salts over taurine-conjugated forms. Genetic analysis of the bsh showed high similarity to the previously sequenced bsh gene from B. animalis and confirmed the usefulness of bile salt hydrolase as a genetic marker for B. animalis identification.